12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botulism antitoxin heptavalent regulatory update

FDA approved a BLA from Cangene for botulism antitoxin heptavalent (BAT) to treat patients showing signs of botulism following documented or suspected exposure to...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >